Longevity Unlocked: From Hormones to Healthspan Economics

Longevity medicine is evolving from a niche wellness pursuit to a legitimate frontier of population health. Once dominated by biohackers and early adopters, the field now sits at the intersection of hormonal therapies, metabolic interventions, and preventive care models — backed by mounting clinical evidence and shifting regulatory signals. With the FDA’s recent removal of the black-box warning on menopausal hormone therapy and a surge in investment into longevity clinics and retail health platforms, a new phase of science-led, consumer-driven longevity is emerging.

For healthcare leaders, the opportunity is matched by complexity. Payers and employers are asking how to fund prevention at scale, providers are determining how to integrate longevity protocols into mainstream care, and innovators are balancing personalization with population-level impact. This discussion explores the clinical, economic, and ethical dimensions of the longevity movement — reframing it from an elite pursuit to a health system and public health opportunity.

Participants will examine what it will take to move beyond “anti-aging” hype toward measurable extensions in healthspan, equitable access to preventive care, and sustainable value across the healthcare ecosystem.

Join us to discuss:

• How are providers, payers, and innovators redefining longevity as an evidence-based discipline rather than a niche trend?

• What reimbursement, regulation, and clinical frameworks will make preventive and regenerative care models scalable?

• Where do the greatest ROI opportunities lie across metabolic, cognitive, and reproductive health?